Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: coukos g. Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. Ann Oncol. 2017. PMID: 28453702 Free PMC article. Clinical Trial.
Early ovarian cancer.
Coukos G, Rubin SC. Coukos G, et al. Curr Treat Options Oncol. 2000 Jun;1(2):129-37. doi: 10.1007/s11864-000-0057-2. Curr Treat Options Oncol. 2000. PMID: 12057050 Review.
Immunotherapy opportunities in ovarian cancer.
Chu CS, Kim SH, June CH, Coukos G. Chu CS, et al. Among authors: coukos g. Expert Rev Anticancer Ther. 2008 Feb;8(2):243-57. doi: 10.1586/14737140.8.2.243. Expert Rev Anticancer Ther. 2008. PMID: 18279065 Review.
Immunotherapy for ovarian cancer: what's next?
Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Kandalaft LE, et al. Among authors: coukos g. J Clin Oncol. 2011 Mar 1;29(7):925-33. doi: 10.1200/JCO.2009.27.2369. Epub 2010 Nov 15. J Clin Oncol. 2011. PMID: 21079136 Free PMC article. Review.
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study.
Simpkins F, Flores A, Chu C, Berek JS, Lucci J 3rd, Murray S, Bauman J, Struemper H, Germaschewski F, Jonak Z, Gardner O, Toso J, Coukos G. Simpkins F, et al. Among authors: coukos g. Cancer Immunol Res. 2013 Sep;1(3):168-78. doi: 10.1158/2326-6066.CIR-13-0098. Epub 2013 Jul 31. Cancer Immunol Res. 2013. PMID: 24777679 Clinical Trial.
Opportunities in immunotherapy of ovarian cancer.
Coukos G, Tanyi J, Kandalaft LE. Coukos G, et al. Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i11-i15. doi: 10.1093/annonc/mdw084. Ann Oncol. 2016. PMID: 27141063 Free PMC article. Review.
Neoantigen-based cancer immunotherapy.
Bobisse S, Foukas PG, Coukos G, Harari A. Bobisse S, et al. Among authors: coukos g. Ann Transl Med. 2016 Jul;4(14):262. doi: 10.21037/atm.2016.06.17. Ann Transl Med. 2016. PMID: 27563649 Free PMC article. Review.
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Monk BJ, Facciabene A, Brady WE, Aghajanian CA, Fracasso PM, Walker JL, Lankes HA, Manjarrez KL, Danet-Desnoyers GH, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G. Monk BJ, et al. Among authors: coukos g. Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4. Clin Cancer Res. 2017. PMID: 27702821 Free PMC article. Clinical Trial.
396 results